Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] [Phase 3]
A Phase 3 clinical trial evaluating pembrolizumab with or without maintenance Sac-TMT (MK-2870) in metastatic squamous non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer [Phase 1]
Phase 1 study evaluating safety and potential efficacy of combining ceritinib with nivolumab in patients with ALK-positive non-small cell lu…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study [Phase 4]
This is a rollover/compassionate-use style update allowing patients already on ceritinib to continue receiving the drug within a Novartis-sp…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer [Phase 2]
This is a Phase 2 clinical trial evaluating petosemtamab in adults with metastatic non-small cell lung cancer, including squamous and non-sq…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease [Phase 1]
Phase 1 study evaluating intravenous and intrathecal nivolumab for leptomeningeal disease in melanoma and non-small cell lung cancer patient…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
An ongoing qualitative study sponsored by the University of Southern California is investigating detection and treatment of non-small cell l…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis [NA]
A clinical trial is evaluating pulsatile high-dose furmonertinib for EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis; …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
A recruiting clinical trial at Peking University People's Hospital is evaluating a cadherin-3 (CDH3) targeted PET imaging agent for lung mal…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC [Phase 2]
Prospective Phase 2 trial assessing real-world outcomes of pembrolizumab in Black patients with non-small cell lung cancer; currently recrui…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) [Phase 2]
This clinical trial update describes a Phase 2 multimodality treatment study for stage III non-small cell lung cancer, currently active but …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
A Phase 1/Phase 2 neoadjuvant trial testing ensartinib in combination with chemotherapy for ALK-positive non-small cell lung cancer, current…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers [Phase 1]
Phase 1 clinical trial update for PF-08046032 in people with advanced cancers; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: FAP-targeted PET/NIR in Lung Malignant Tumors
An ongoing clinical trial is evaluating a fibroblast activation protein (FAP)-targeted PET/near-infrared imaging agent in non-small cell lun…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) [Phase 2]
Phase 2 substudy MK-3475-01I/KEYMAKER-U01I evaluating investigational pembrolizumab-based therapy in previously treated stage IV squamous no…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) [Phase 3]
This entry describes an ongoing Phase 3 clinical trial evaluating pembrolizumab in combination with berahyaluronidase alfa (MK-3475A) for ne…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer [Phase 2]
A Phase 2 clinical trial is evaluating hippocampus-sparing radiotherapy in combination with osimertinib for symptomatic brain metastases in …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
This clinical trial update discusses a Pfizer-sponsored study evaluating dacomitinib in patients with non-small cell lung cancer, with the t…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% [Phase 3]
This is a Phase 3 clinical trial update describing a study that compares nivolumab plus relatlimab with chemotherapy against pembrolizumab p…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types [Phase 1]
IDEAYA Biosciences is conducting a Phase 1 study of IDE034 in adults with multiple locally advanced or metastatic solid tumors; the trial is…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab [Phase 2]
A Phase 2 clinical trial investigating neoadjuvant low-dose stereotactic body radiotherapy combined with ipilimumab and nivolumab for non-sm…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]
A clinical trial update for AU-007, a monoclonal antibody that binds IL-2 and inhibits IL-2Rα binding, being studied in unresectable locally…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers [Phase 1]
Phase 1 study of AB598 as monotherapy and in combination across multiple advanced cancers is ongoing, with status active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) [Phase 2]
A Phase 2 study evaluating pembrolizumab (MK-3475) in combination with investigational agents for resectable non-small cell lung cancer is c…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) [Phase 2]
A Phase II clinical trial evaluating Y-90 labeled Fibroblast Activation Protein Inhibitor therapy in patients with non-small cell lung cance…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC [Phase 1]
Phase 1 clinical trial update for CD40L-augmented tumor-infiltrating lymphocytes in EGFR, ALK, ROS1 or HER2-driven non-small cell lung cance…